MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
72.40
+1.55
+2.19%
Closed 18:14 02/06 EST
OPEN
71.17
PREV CLOSE
70.85
HIGH
74.40
LOW
71.00
VOLUME
30.00K
TURNOVER
517.71K
52 WEEK HIGH
240.00
52 WEEK LOW
4.275
MARKET CAP
77.49M
P/E (TTM)
-0.8554
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRB last week (0202-0206)?
Weekly Report · 1h ago
3 ‘Strong Buy’ Stocks to Buy Now, 2/6/2026, According to Top Analysts
TipRanks · 2d ago
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target
TipRanks · 2d ago
Spruce Biosciences Highlights Promising Long-Term Tralesinidase Data
TipRanks · 3d ago
Spruce Biosciences Reports Long-Term Efficacy of Tralesinidase Alfa in Sanfilippo Syndrome Type B
Reuters · 3d ago
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Barchart · 3d ago
Spruce Biosciences Appoints Daven Mody and Bruno Gagnon to Executive Leadership Team
Reuters · 5d ago
Weekly Report: what happened at SPRB last week (0126-0130)?
Weekly Report · 02/02 09:31
More
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

Webull offers Spruce Biosciences Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.